Crystal NAX Showcases Under the Crystal Pharmatech Family at CPHI Frankfurt 2025
October 30, 2025 | New Jersey
Crystal NAX successfully exhibited at CPHI Frankfurt 2025, marking its first public presentation under the Crystal Pharmatech family, alongside Crystal Bio Solutions (CBS). The event represented an important milestone in Crystal Pharmatech’s expansion into nucleic acid–based technologies.
Throughout the event, the team engaged with long-standing partners and new industry connections to introduce the group’s expanding capabilities in nucleic acid therapeutics, including RNA design, synthesis, delivery technologies, and analytical characterization. Visitors also showed strong interest in biologics CMC analytics, bioanalysis & biomarkers, and quantitative clinical pharmacology services provided by Crystal Bio Solutions, a member of Crystal Pharmatech.
The response to Crystal NAX at CPHI Frankfurt has been extremely encouraging,” said the CEO of Crystal Pharmatech. “We saw strong and growing demand for nucleic acid–based research and development, particularly in RNA design, delivery, and analytical characterization. Crystal NAX significantly strengthens our capabilities in this rapidly evolving field and allows us to better support our partners as they advance next-generation therapeutics.
The strong engagement across small molecules, biologics, and nucleic acids reinforced Crystal Pharmatech’s integrated platform approach to drug development. With the addition of Crystal NAX, the group remains committed to serving as a trusted, long-term partner, providing scientifically rigorous, flexible, and high-quality solutions to help clients accelerate innovation from discovery through clinical development.